Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 9/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 3/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23722126 | 0.99 | SOS1 (0.33) | SOS1MPOMAPTOPRM1OPRK1 | |
| SCHEMBL23745754 | 0.93 | SOS1 (0.36) | SOS1MPOMAPTOPRM1OPRK1 | |
| SCHEMBL23745631 | 0.92 | MPO (0.36) | SOS1MPOMAPTOPRM1OPRK1 | |
| SCHEMBL23745472 | 0.92 | MPO (0.36) | SOS1MPOMAPTOPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL23721916 | 0.92 | MPO (0.36) | SOS1MPOMAPTOPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL23722007 | 0.91 | MPO (0.36) | SOS1MPOMAPTOPRM1OPRK1 | |
| SCHEMBL23722039 | 0.91 | SOS1 (0.43) | SOS1MPOOPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL23722073 | 0.90 | SOS1 (0.43) | SOS1MPOOPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL23721969 | 0.90 | SOS1 (0.43) | SOS1MPOOPRM1OPRK1OPRL1 | |
| SCHEMBL23745580 | 0.84 | SOS1 (0.50) | SOS1MPOMAPTHTR4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | SOS1 2902/4885MPO 17/4885MAPT 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.